Response to treatment with placebo, medication or psychotherapy in severe non-psychotic major depressive disorder

Current Psychiatry Reviews

Volumn 6, Issue 1, 2010, Pages 28-45

  Dunlop, Boadie W ^a   Aaron, Margo H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Clinical trial; Cognitive behavioral therapy; Depression; Psychotherapy; Review

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PINDOLOL; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG THERAPY; HAMILTON SCALE; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MELANCHOLIA; METHODOLOGY; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PATIENT CODING; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION; REVIEW; SAMPLING; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77950248582     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340010790596526     Document Type: Review

References (209)

1. First MB, Pincus HA, Levine JB, et al. Clinical utility as a criterion for revising psychiatric diagnoses. Am J Psychiatry 2004; 161: 946-54.
2. Melartin TK, Rytsala HJ, Leskela US, et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry 2004; 65: 810-19.
3. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Recovery in major depressive disorder: Analysis with the life table and regression models. Arch Gen Psychiatry 1982; 39: 905-10.
4. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49: 809-16.
5. O'Leary D, Costello F, Gormley N, Webb M. Remission onset and relapse in depression: An 18-month prospective study of course for 100 first admission patients. J Affect Disord 2000; 57: 159-71.
6. Parker G, Hadzi-Pavlovic D, Brodaty H, et al. Predicting the course of melancholic and nonmelancholic depression: A naturalistic comparison study. J Nerv Ment Dis 1992; 180: 693-702.
7. Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: A two-year prospective follow-up study. Psychol Med 1995; 25: 1161-70.
8. Mueller TI, Keller MB, Leon AC, et al. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 1996; 53: 794-99.
9. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147: 621-24.
10. Sargeant J, Bruce ML, Florio LP, Weissman MM. Factors associated with 1-year outcome of major depression in the community. Arch Gen Psychiatry 1990; 47: 519-26.
11. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the national comorbidity survey. J Affect Disord 1997; 45: 19-30.
12. Hoencamp E, Haffmans PMJ, Duivenvoorden H, Knegtering H, Dijken WA. Predictors of (non-)response in depressed outpatients treated with a three-phase sequential medication strategy. J Affect Disord 1994; 31: 235-46.
13. Keitner GI, Ryan CE, Miller IW, Norman WH. Recovery and major depression: Factors associated with twelve-month outcome. Am J Psychiatry 1992; 149: 93-99.
14. Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry 1992; 161: 633-37.
15. Bulik C, Carpenter L, Kupfer D, Frank E. Features associated with suicide attempts in recurrent major depression. J Affect Disord 1990; 18: 29-37.
16. O'Leary DA, Lee AS. Seven year prognosis in depression mortality and readmission risk in the Nottingham ECT cohort. Br J Psychiatry 1996; 169: 423-29.
17. Lee AS, Murray RM. The long-term outcome of Maudsley depressives. Br J Psychiatry 1988; 153: 741-51.
18. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988; 153: 752-57.
19. Gormley N, O'Leary D, Costello F. First admissions for depression: is the "no-treatment interval" a critical predictor of time to remission? J Affect Disord 1999; 54: 49-54.
20. Surtees PG, Barkley C. Future imperfect: The long-term outcome of depression. Br J Psychiatry 1994; 164: 327-41.
21. Frank EF, Kupfer DJ, Hamer T, Grochocinski VJ, McEachran AB. Maintenance treatment and psychobiologic correlates of endogenous subtypes. J Affect Disord 1992; 25: 181-89.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg 1960; 23: 50-55.
23. Schatzberg A. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999; 60 (Suppl 4): 14-21.
24. Schatzberg AF. Treatment of severe depression with the selective serotonin reuptake inhibitors. Depress Anxiety 1996; 4: 182-89.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-89.
26. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51: 161-70.
27. Sonwawalla SB, Fava M. Severe Depression: is there a best approach? CNS Drugs 2001; 15: 765-76.
28. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 2003; 77: 255-60.
29. Association AP. Diagnostic and statistical manual of mental disorders (DSM-IV). 4 ed. Washington, D.C., American Psychiatric Association 1994.
30. Gastpar M, Ngo Khac T, Gilsdorf U, Baumann P. Comparison of oral and intravenous treatment of depressive states: preliminary results of a WHO collaborative study. Clin Neuropharmacol 1986; 9 (Suppl 4) 4: 434-6.
31. Guy W. ECDEU assessment manual for psychopharmacology. Rockville (MD), US Dept Health, Education and Welfare 1976.
32. Mendlowicz MV, Rapaport MH, Thompson P, et al. A comparison of descriptive characteristics of male outpatients and inpatients with affective disorders. Int Clin Psychopharmacol 1998; 13: 245-52.
33. Pinder R, Blum A, Stulemeijer S, et al. A double-blind multicenter trial comparing the efficacy and side-effects of mianserin and chlorimipramine in depressed in- and outpatients. Int Pharmacopsychiatry 1980; 15: 218-27.
34. Buysse DJ, Jarrett DB, Miewald JM, Kupfer DJ, Greenhouse JM. Minute-by-minute analysis of REM sleep timing in major depression. Biol Psychiatry 1990; 28: 911-25.
35. Friedman R. Hospital treatment of psychiatric emergencies. Psychiatr Clin North Am 1983; 6: 293-303.
36. Lewis AJ. Melancholia: A clinical survey of depressive states. J Mental Sci 1934; 80: 227-378.
37. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005; 30: 445-60.
38. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSMIV? Am J Psychiatry 1992; 149: 733-45.
39. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: A meta-analytic review. J ECT 2004; 20: 13-20.
40. McCullough JP, Jr., Klein DN, Keller MB, et al. Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction. J Abnorm Psychol 2000; 109: 419-27.
41. Guyatt GH, Juniper EF, Walter SD, Griffin LE, Goldstein RS. Interpreting treatment effects in randomised trials. Br Med J 1998; 316: 690-93.
42. Disorder WGoB. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry 2002; 159 (Suppl): 1-50.
43. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002; 287: 1840-47.
44. Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 2000; 56: 271-8.
45. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the food and drug administration database. J Clin Pharmacol 2002; 22: 40-45.
46. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39:145-50.
47. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45.
48. Brown WA, Dornseif BE, Wernicke JF. Placebo response in depression: A search for predictors. Psychiatr Res 1988; 26: 259-64.
49. Brown WA, Johnson MF, Chen M-G. Clinical features of depressed patients who do and do not improve with placebo. Psychiatr Res 1992; 41: 203-14.
50. Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial. J Affect Disord 1988; 14: 83-95.
51. Stewart JW, Quitkin FM, Liebowitz MR, et al. Efficacy of desipramine in depressed outpatients: Response according to Research Diagnostic Criteria diagnoses and severity of illness. Arch Gen Psychiatry 1983; 40: 202-07.
52. Rabkin JG, Stewart JW, McGrath PJ, et al. Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatr Res 1987; 21: 9-22.
53. Fairchild CJ, Rush AJ, Vasavada N, Giles DE, Khatami M. Which depressions respond to placebo? Psychiatry Res 1986; 18: 217-26.
54. Wilcox CS, Cohn JB, Linden RD, et al. Predictors of placebo response: A retrospective analysis. Psychopharmacol Bull 1992; 28: 157-62.
55. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 731-40.
56. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Br J Clin Res 1991; 2: 125-32.
57. Feighner JP, Cohn JB, Fabre LF, et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993; 28: 71-9.
58. Angst J, Delini-Stula A, Stabl M, Stassen HH. Is a cut-off score a suitable measure of treatment outcome in short-term trials in depression? A methodological meta-analysis. Hum Psychopharmacol 1993; 8: 311-17.
59. Pfohl B, Stangl D, Zimmerman M. The implications of DSM-III personality disorders for patients with major depression. J Affect Disord 1984; 7: 309-18.
60. Reisby N, Gram LF, Bech P, et al. Imipramine: Clinical effects and pharmacokinetic variability. Psychopharmacology (Berl) 1977; 54: 263-72.
61. Raskin A, Schulterbrandt JG, Reatig N, McKeon JJ. Differential response to chlorpromazine, imipramine, and placebo: A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry 1970; 23: 164-73.
62. Raskin A, Crook TH. The endogenous-neurotic distinction as a predictor of response to antidepressant drugs. Psychol Med 1976; 6: 59-70.
63. Paykel ES. Depressive typologies and response to amitriptyline. Br J Psychiatry 1972; 120: 147-56.
64. Nelson JC, Mazure CM, Jatlow PI. Does melancholia predict response in major depression? J Affect Disord 1990; 18: 157-65.
65. Mazure CM, Nelson J, Jatlow PI. Predictors of hospital outcome without antidepressants in major depression. Psychiatr Res 1990; 33: 51-58.
66. Rickels K, Feighner JP, Smith WT. Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. Arch Gen Psychiatry 1985; 42: 134-41.
67. Stewart JW, McGrath PJ, Liebowitz MR, et al. Treatment outcome validation of DSM-III depressive subtypes: Clinical usefulness in outpatients with mild to moderate depression. Arch Gen Psychiatry 1985; 42: 1148-53.
68. Paselow ED, Sanfilipo MP, Difiglia C, Fieve RR. Melancholic/-endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 1992; 149: 1324-34.
69. Heiligenstein JH, Tollefson GD, Faries DE. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994; 30: 163-73.
70. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995; 56: 450-58.
71. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28-34.
72. Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression: Meta-analysis of imipramine and moclobemide versus placebo. Eur Psychiatry 1994; 9: 129-36.
73. Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991; 4: 125-30.
74. Kocsis JH, Frances AJ, Voss CB, et al. Imipramine treatment for chronic depression. Arch Gen Psychiatry 1988; 45: 253-57.
75. Downing RW, Rickels K. Predictors of response to amitriptyline and placebo in three outpatient treatment settings. J Nerv Ment Dis 1973; 156: 109-29.
76. Rogers SC, Clay PM. A statistical review of controlled trials of imipramine and placebo in the treatment of depressive illnesses. Br J Psychiatry 1975; 127: 599-603.
77. Stewart JW, McGrath PJ, Quitkin FM, et al. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: Differential response to phenelzine, imipramine, and placebo. Arch Gen Psychiatry 1989; 46: 1080-87.
78. Schatzberg A, Kraemer HC. Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biol Psychiatry 2000; 47: 736-44.
79. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7(Suppl 1): 11-17.
80. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 2004; 3: 3.
81. Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology (Berl) 1995; 119: 277-81.
82. Rahman MK, Akhtar MJ, Savla NC, et al. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991; 4: 255-58.
83. Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989; 4: 81-88.
84. Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987; 75: 478-86.
85. Mertens C, Pintens H. Paroxetine in the treatment of depression: A double-blind multicenter study versus mianserin. Acta Psychiatr Scand 1988; 77: 683-88.
86. de Wilde J, Mertens C, Fredricson Overo K, Hopfner Petersen HE. Citalopram versus mianserin: A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985; 72: 89-96.
87. Barbui C, Hotopf M. Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001; 178: 129-44.
88. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram: A meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994; 9: 35-40.
89. Thase ME. Effectiveness of antidepressants: Comparative remission rates. J Clin Psychiatry 2003; 64: 3-7.
90. Group DUA. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study. Psychopharmacology (Berl) 1986; 90: 131-38.
91. Group DUA. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289-99.
92. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139-43.
93. Guelfi JD, Dreyfus JF, Pichot P. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 1983; 15: 411S-17S.
94. de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24: 62-67.
95. Guelfi JD, Payan C, Fermanian J, Pedarriosse AM. Moclobemide versus clomipramine in endogenous depression: A double-blind randomised clinical trial. Br J Psychiatry 1992; 160: 519-24.
96. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992; 7: 91-94.
97. Beasley CM, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. Ann Clin Psychiatry 1993; 5: 199-208.
98. Moller HJ, Berzewski H, Eckmann F, et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993; 26: 75-8.
99. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994; 14: 241-46.
100. Richou H, Ruimy P, Charbaut J, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995; 10: 263-71.
101. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol 1995; 15: 16S-23S.
102. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000; 15: 29-34.
103. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S, Group M-VS. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425-31.
104. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 2003; 18: 113-19.
105. van den Broek WW, Birkenhager TK, Mulder PGH, Bruijn JA, Moleman P. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology 2004; 175: 481-86.
106. Group DUA. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993; 28: 105-16.
107. Bruijn JA, Moleman P, Mulder PGH, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) 1996; 127: 231-37.
108. Feighner J, Targum SD, Bennett ME, et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 1998; 59: 246-53.
109. Kasper S, Moeller HJ, Montgomery SA, Zondag E. Antidepressant efficacy in relation to item analysis and severity of depression: A placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995; 9: 3-12.
110. Flament MF, Lane RM, Zhu R, Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999; 14: 259-75.
111. Lepine JP, Goger J, Blashko C, et al. A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 2000; 15: 263-71.
112. Versiani M, Moreno R, Ramakers-vanMoorsel CJA, Schutte AJ. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19: 137-46.
113. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131-37.
114. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66: 1312-20.
115. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22:1331-41.
116. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993; 8: 243-45.
117. Kasper S, Zivkov M, Roes KCB, Pols AG. Pharmacological treatment of severely depressed patients: A meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997; 7: 115-24.
118. Mongtomery S, Ferguson JM, Schwartz GE. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003; 23: 45-50.
119. Feiger AD, Flament MF, Boyer P, Gillespie JA. Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. Int Clin Psychopharmacology 2003; 18: 203-10.
120. Dunner DL, Lipschitz A, Pitts CD, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: Post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther 2005; 27: 1901-11.
121. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-31.
122. Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int Clin Psychopharmacol 2008; 23: 181-7.
123. Davidson J, Miller R, Van Wyck Fleet J, et al. A double-blind comparison of bupropion and amitriptyline in depressed inpatients. J Clin Psychiatry 1983; 44: 115-17.
124. Ginestet D, Alby JM, Besancon G, et al. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989; 4: 37-40.
125. Klok CJ, Brouwer GJ, Van Praag HM, Doogan D. Fluvoxamine and clomipramine in depressed patients: A double-blind clinical study. Acta Psychiatr Scand 1981; 64: 1-11.
126. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59: 268-75.
127. Schweizer E, Rynn M, Mandos LA, et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. Int Clin Psychopharmacol 2001; 16:137-43.
128. Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13: 381-92.
129. Simpson GM, Lee J, Cuculic Z, Kellner R. Two dosages of imipramine in hospitalized endogenous and neurotic depressives. Arch Gen Psychiatry 1976; 33: 1093-102.
130. Gram LF. Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clin Neuropharmacol 1990; 13: 35-44.
131. Khan A, Kolts RL, Thase ME, Krishnan KRR, Brown WA. Research design features and patient characteristics associated with the outcome of antidepressant trials. Am J Psychiatry 2004;161: 2045-49.
132. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants: Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297-303.
133. Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989; 25: 71-9.
134. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53 (Suppl. 6): 21-6.
135. Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128-34.
136. Birkenhager TK, van den Broek WW, Mulder PG, Bruijn JA, Moleman P. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. Am J Psychiatry 2004; 161: 2060-65.
137. Bruijn JA, Moleman P, Mulder PGH, van den Broek WW. Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 1998; 59: 657-63.
138. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15: 217-22.
139. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41: 201-10.
140. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19: 177-82.
141. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448-52.
142. Baumann P, Souche A, Montaldi S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-14.
143. Cappiello A, McDougle CJ, Delgado PL, et al. Lithium and desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study. Int Clin Psychopharmacol 1998; 13: 191-98.
144. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82.
145. Schulberg HC, Pilkonis PA, Houck P. The severity of major depression and choice of treatment in primary care practice. J Consult Clin Psychol 1998; 66: 932-38.
146. Thase ME, Bowler K, Harden T. Cognitive behavior therapy of endogenous depression: II. Preliminary findings in 16 unmedicated inpatients. Behav Ther 1991; 22: 469-77.
147. Thase ME, Simons AD, Reynolds CF, III. Psychobiological correlates of poor response to cognitive behavior therapy: potential indications for antidepressant pharmacotherapy. Psychopharmacol Bull 1993; 29: 293-301.
148. Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54: 1009-15.
149. Klein DF. A checklist for developing and reviewing comparative treatment evaluations in the areas of psychotherapy and pharmacotherapy. In: Janowsky DS Ed. Psychotherapy indications and outcomes. Washington, D.C., American Psychiatric Press 1999; pp. 367-81.
150. de Jonghe F, Kool S, van Aalst G, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001; 64: 217-29.
151. de Jonghe F, Hendriksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatry 2004; 185: 37-45.
152. Meterissian GB, Bradwejn J. Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: Was adequate pharmacotherapy provided? J Clin Psychopharmacol 1989; 9: 334-39.
153. de Jong R, Treiber R, Henrich G. Effectiveness of two psychological treatments for inpatients with severe and chronic depressions. Cognit Ther Res 1986; 10: 645-63.
154. Elkin I, Gibbons RD, Shea M, Shaw BF. Science is not a trial (but it can sometimes be a tribulation). J Consult Clin Psychol 1996; 64: 92-103.
155. Elkin I, Gibbons RD, Shea MT, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995; 63: 841-47.
156. Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression: Singly and in combination. Arch Gen Psychiatry 1992; 49: 774-81.
157. McLean P, Taylor S. Severity of unipolar depression and choice of treatment. Behav Res Ther 1992; 30: 443-51.
158. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs Medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005; 62: 409-16.
159. Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74: 658-70.
160. Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioral therapy for depression. Br J Psychiatry 2007; 190: 496-502.
161. DeRubeis RJ, Gelfand LA, Tang TZ, Simons AD. Medications versus cognitive behavior therapy for severely depressed outpatients: Mega-analysis of four randomized comparisons. Am J Psychiatry 1999; 156: 1007-13.
162. Rush AJ, Beck AT, Kovacs M, Hollon SD. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognit Ther Res 1977; 1: 17-37.
163. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy, singly and together in the treatment of depression. Arch Gen Psychiatry 1984; 41: 33-41.
164. Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992; 49: 802-8.
165. Kovacs M, Rush AJ, Beck AT, Hollon SD. Depressed outpatients treated with cognitive therapy or pharmacotherapy. Arch Gen Psychiatry 1981; 38: 33-9.
166. Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression: Sustained improvement over one year. Arch Gen Psychiatry 1986; 43: 43-8.
167. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62: 417-22.
168. Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up: Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1992; 49: 782-87.
169. Miller IW, Norman WH, Keitner GI. Cognitive-behavioral treatment of depressed inpatients: Six- and twelve-month followup. Am J Psychiatry 1989; 146: 1274-79.
170. Weissman MM. The psychological treatment of depression: evidence for the efficacy of psychotherapy alone, in comparison with, and in combination with pharmacotherapy. Arch Gen Psychiatry 1979; 36: 1261-69.
171. Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: A comprehensive review of controlled outcome research. Psychol Bull 1990; 108: 30-49.
172. Wexler BE, Cicchetti DV. The outpatient treatment of depression: Implications of outcome research for clinical practice. J Nerv Ment Dis 1992; 180: 277-86.
173. Conte HR, Plutchik R, Wild KV, Karasu TB. Combined psychotherapy and pharmacotherapy for depression: A systematic analysis of the evidence. Arch Gen Psychiatry 1986; 43: 471-79.
174. Pampallona S, Bollini P, Tibalbi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: A systematic review. Arch Gen Psychiatry 2004; 61: 714-9.
175. Bowers WA. Treatment of depressed inpatients. Cognitive therapy plus medication, relaxation plus medication, and medication alone. Br J Psychiatry 1990; 156: 73-8.
176. Zimmerman M, Coryell W, Pfohl B. Melancholic subtyping: a qualitative or quantitative distinction. Am J Psychiatry 1986; 143: 98-100.
177. Davidson J, Turnbull C, Strickland R, Belyea M. Comparative diagnostic criteria for melancholia and endogenous depression. Arch Gen Psychiatry 1984; 41: 506-11.
178. Duggan CF, Lee AS, Murray RM. Do different subtypes of hospitalized depressives have different long-term outcomes? Arch Gen Psychiatry 1991; 48: 308-12.
179. Duggan CF, Lee AS, Murray RM. Does personality predict longterm outcome in depression? Br J Psychiatry 1990; 157: 19-24.
180. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response. Arch Gen Psychiatry 1976; 33: 1479-89.
181. Rush JA, Weissenburger JE. Melancholic symptom features and DSM-IV. Am J Psychiatry 1994; 151: 489-98.
182. Carney MWP, Roth M, Garside RF. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 1965; 111: 659-74.
183. Spitzer R, Endicott J, Robins E. Research diagnostic criteria for a selected group of functional disorders. 3rd ed. New York, Biometrics Research Division, New York State Psychiatric Institute 1977.
184. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3 ed. Washington, D.C., American Psychiatric Association 1980.
185. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd, revised ed. Washington, D.C.: American Psychiatric Association 1987.
186. Zimmerman M, Coryell W, Pfohl B, Stangl D. The validity of four definitions of endogenous depression: II. Clinical, demographic, familial, and psychosocial correlates. Arch Gen Psychiatry 1986; 43: 234-44.
187. Rush AJ, Giles DE, Jarrett RB, et al. Reduced REM latency predicts response to tricylclic medication in depressed outpatients. Biol Psychiatry 1989; 26: 61-72.
188. Georgotas A, McCue R, Cooper T, et al. Clinical predictors of resonse to antidepressants in elderly patients. Biol Psychiatry 1987; 22: 733-40.
189. Coryell W, Turner R. Outcome with desipramine therapy in subtypes of nonpsychotic major depression. J Affect Disord 1985; 9: 149-54.
190. Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust N Z J Psychiatry 2002; 36: 384-91.
191. Perry PJ. Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39: 1-6.
192. Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry 1988; 153: 64-68.
193. Prusoff BA, Weissman MM, Klerman GL, Rounsaville BJ. Research diagnostic criteria subtypes of depression: Their role as predictors of differential response to psychotherapy and drug treatment. Arch Gen Psychiatry 1980; 37: 796-801.
194. Cornelius JR, Salloum IM, Mezzich J, et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry 1995; 152: 358-64.
195. Malone KM, Haas GL, Sweeny JA, Mann JJ. Major depression and the risk of suicide attempt. J Affect Disord 1995; 34: 173-85.
196. Van Praag HM, Plutchik R. Depression type and depression severity in relation to risk of violent suicide attempt. Psychiatry Res 1984; 12: 333-38.
197. Oquendo MA, Kamali M, Ellis SP, et al. Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry 2002; 159: 1746-51.
198. Zweig RA, Hinrichsen GA. Factors associated with suicide attempts by depressed older adults: a prospective study. Am J Psychiatry 1993; 150: 1687-92.
199. Szanto K, Mulsant BH, Houck P, Dew MA, Reynolds CF, III. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60: 610-17.
200. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 2003; 60: 817-26.
201. Hendin H, Maltsberger JT, Haas AP, Szanto K, Rabinowicz H. Desperation and other affective states in suicidal patients. Suicide Life Threat Behav 2004; 34: 386-94.
202. Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J Nerv Ment Dis 1999; 187: 360-68.
203. Rifai A, George CJ, Stack JA, Mann JJ, Reynolds CF. Hopelessness in suicide attempters after acute treatment of major depression in late life. Am J Psychiatry 1994; 151: 1687-90.
204. Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment- resistant depression: Prevalence and impact on treatment outcome. J Nerv Ment Dis 2003; 191: 444-49.
205. Szanto K, Mulsant BH, Houck PR, et al. Treatment outcome in suicidal vs. non-suicidal elderly patients. Am J Geriatr Psychiatry 2001; 9: 261-68.
206. Bradvik L, Berglund M. Treatment and suicide in severe depression: A case-control study of antidepressant therapy at last contact before suicide. J ECT 2000; 16: 399-408.
207. Taiminen T. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand 1993; 87: 45-57.
208. Modestin J. Effect of psychopharmacology on suicide risk in discharged psychiatric patients. Acta Psychiatr Scand 1992; 85:173-75.
209. Fossati P, Hevenor SJ, Lepage M, et al. Distributed self in episodic memory: neural correlates of successful retrieval of self-encoded positive and negative personality traits. Neuroimage 2004; 22:1596-604.